Aerovate Therapeutics Inc
NASDAQ:JBIO
ROA
Return on Assets
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
ROA Across Competitors
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| US |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
77.7m USD |
-67%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-391%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
323.7B USD |
3%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.1B USD |
7%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
133.7B USD |
11%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112B USD |
-4%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-67%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
119.3B AUD |
7%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.7B USD |
13%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-21%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.8B USD |
-7%
|
Aerovate Therapeutics Inc
Glance View
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.
See Also
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
Based on Aerovate Therapeutics Inc's most recent financial statements, the company has ROA of -67%.
You don't have any saved screeners yet